Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MERTK | Q12866 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | TXNRD1 | Q16881 | 4/20 | 0.47 |
| ▸ | GSR | P00390 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | CTSH | P09668 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29392605 | 1.00 | MERTK (0.51) | MERTKMAPTTXNRD1GSRTDP1 | |
| SCHEMBL56616 | 0.83 | MAPT (0.50) | MERTKMAPTTXNRD1GSRTDP1 | |
| SCHEMBL29364858 | 0.83 | MAPT (0.50) | MERTKMAPTTXNRD1GSRTDP1 | |
| SCHEMBL5971901 | 0.80 | ALDH1A1 (0.61) | MERTKMAPTTXNRD1GSRTDP1 | |
| SCHEMBL30875970 | 0.80 | NOS3 (0.48) | MAPTTDP1L3MBTL1POLBTSHR | |
| SCHEMBL539616 | 0.80 | NOS3 (0.48) | MAPTTDP1L3MBTL1POLBTSHR | |
| SCHEMBL1128565 | 0.80 | TSHR (0.44) | MERTKMAPTTXNRD1TDP1L3MBTL1 | |
| SCHEMBL30810188 | 0.79 | CTSB (0.54) | MAPTTDP1L3MBTL1POLBTSHR | |
| SCHEMBL1135629 | 0.79 | CTSB (0.54) | MAPTTDP1L3MBTL1POLBTSHR | |
| SCHEMBL136263 | 0.78 | CTSB (0.53) | MERTKMAPTTDP1L3MBTL1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 420 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105541703-A | Triamine monomer containing pyridine structure and preparation method thereof | UNIV JILIN | 2016-05-04 | — | — | CN | claimed |
| CN-102775404-A | Method for synthesizing 5-chloro-4-azaindole | CHEMFUTURE PHARMATECH JIANGSU LTD | 2012-11-14 | — | — | CN | claimed |
| CN-122036699-A | THR-beta modulators and methods of use thereof | 阿利戈斯治疗公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-4731262-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A QUINAZOLINE COMPOUND | Astellas Pharma Inc. (JP) | 2026-04-29 | — | — | EP | disclosed |
| EP-4673137-A1 | NBD1 MODULATORS AND METHODS OF USING THE SAME | Sionna Therapeutics Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4634169-A1 | 3-FLUORO-4-HYDROXYBENZMIDE-CONTAINING INHIBITORS AND/OR DEGRADERS AND USES THEREOF | Pfizer Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| WO-2025215153-A1 | PRMT5 INHIBITORS | Ryvu Therapeutics S.A. (PL) | 2025-10-16 | — | — | WO | disclosed |
| US-20250304561-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2025-10-02 | — | — | US | disclosed |
| EP-4618977-A1 | LRRK2 INHIBITORS AND USES THEREOF | Neuron23, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-3463362-B1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME LLC (US) | 2025-09-03 | — | — | EP | disclosed |
| EP-4559906-A1 | HETEROCYCLIC COMPOUND THAT ACTS ON G12D MUTANT KRAS PROTEIN | Astellas Pharma Inc. (JP) | 2025-05-28 | — | — | EP | disclosed |
| EP-0916670-A2 | Pyrrolo-(3,2-b) pyridines and their use as 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 1999-05-19 | — | — | EP | disclosed |
| US-5905084-A | 5-SUBSTITUTED-3-(PIPERIDIN-4-YL)- AND -3-(1,2,3,6-TETRAHYDROPYRIDIN-4-YL)PYRROLO(3,2-B)PYRIDINES; SIDE EFFECT REDUCTION; NERVOUS SYTEM AND PSYCHOLOGICAL DISORDERS | ELI LILLY AND COMPANY (US) | 1999-05-18 | — | — | US | disclosed |
| US-5874427-A | MIGRAINE | ELI LILLY AND COMPANY (US) | 1999-02-23 | — | — | US | disclosed |
| EP-0892797-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-01-27 | — | — | EP | disclosed |
| CN-1200119-A | (METHYLSULFONYL) PHENYL-2- (5H) -FURANONE AS CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA INC (CA) | 1998-11-25 | — | — | CN | disclosed |
| EP-0875513-A1 | Substituted heteroaromatic 5-HT 1F agonists | ELI LILLY AND COMPANY (US) | 1998-11-04 | — | — | EP | disclosed |
| WO-1998046570-A1 | SUBSTITUTED HETEROAROMATIC 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 1998-10-22 | — | — | WO | disclosed |
| WO-1997030992-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-08-28 | — | — | WO | disclosed |
| EP-0272533-A2 | Substituted phenoxypyridines | BAYER AG (DE) | 1988-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304561-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | THRB, THRA, TRHR | MERTK 1124/4885MAPT 1383/4885TXNRD1 1278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.